Pharrel Wiliams
Shares of Geron (NASDAQ:GERN) traded lower for the third straight session on Thursday as Scotiabank downgraded the U.S. biotech, citing potential challenges to the commercial rollout of its blood cancer therapy, Rytelo.
Analyst Greg Harrison lowered his rating to Sector